X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (16063) 16063
Newspaper Article (1604) 1604
Newsletter (698) 698
Magazine Article (242) 242
Book Chapter (18) 18
Conference Proceeding (16) 16
Transcript (14) 14
Dissertation (4) 4
Book / eBook (2) 2
Publication (2) 2
Reference (2) 2
Streaming Video (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (15184) 15184
science & technology (11507) 11507
life sciences & biomedicine (10772) 10772
hiv infections - drug therapy (10444) 10444
anti-hiv agents - administration & dosage (8547) 8547
anti-hiv agents - therapeutic use (8385) 8385
female (8144) 8144
male (7519) 7519
adult (6490) 6490
infectious diseases (5730) 5730
hiv (5499) 5499
antiviral agents (5372) 5372
aids/hiv (4337) 4337
middle aged (3907) 3907
anti-hiv agents (3696) 3696
drug therapy (3505) 3505
immunology (3489) 3489
aids (3367) 3367
hiv infection (3046) 3046
anti-hiv agents - adverse effects (2999) 2999
drug therapy, combination (2882) 2882
human immunodeficiency virus--hiv (2799) 2799
pharmacology & pharmacy (2734) 2734
hiv infections - virology (2712) 2712
viral load (2435) 2435
hiv infections - prevention & control (2430) 2430
cd4 lymphocyte count (2346) 2346
treatment outcome (2132) 2132
hiv-1 - drug effects (2121) 2121
virology (2031) 2031
research (1932) 1932
antiretroviral therapy (1865) 1865
health aspects (1864) 1864
anti-hiv agents - pharmacology (1832) 1832
drug administration schedule (1828) 1828
adolescent (1771) 1771
dosage and administration (1760) 1760
microbiology (1736) 1736
highly active antiretroviral therapy (1733) 1733
anti-hiv agents - pharmacokinetics (1667) 1667
antiretroviral therapy, highly active (1550) 1550
antiretroviral drugs (1544) 1544
young adult (1534) 1534
hiv infections - immunology (1516) 1516
risk factors (1481) 1481
care and treatment (1469) 1469
pregnancy (1459) 1459
hiv infections - complications (1441) 1441
hiv infections - transmission (1424) 1424
hiv infections - epidemiology (1407) 1407
acquired immune deficiency syndrome--aids (1406) 1406
animals (1399) 1399
public, environmental & occupational health (1307) 1307
hiv-1 (1238) 1238
analysis (1197) 1197
tenofovir (1178) 1178
abridged index medicus (1164) 1164
reverse transcriptase inhibitors - therapeutic use (1115) 1115
human immunodeficiency virus (1112) 1112
reverse transcriptase inhibitors - administration & dosage (1085) 1085
prevention (1062) 1062
child (1037) 1037
patient compliance (1024) 1024
hiv patients (1014) 1014
hiv-1 - genetics (999) 999
cohort studies (996) 996
aged (993) 993
drugs (974) 974
virus diseases (968) 968
adenine - analogs & derivatives (954) 954
infectious disease transmission, vertical - prevention & control (943) 943
acquired immunodeficiency syndrome - drug therapy (942) 942
drug interactions (935) 935
research article (916) 916
general & internal medicine (913) 913
united states (911) 911
medicine, general & internal (906) 906
time factors (898) 898
retrospective studies (855) 855
pharmaceutical industry (847) 847
hiv/aids (846) 846
infant, newborn (826) 826
zidovudine - administration & dosage (818) 818
medicine (806) 806
rna, viral - blood (802) 802
drug resistance, viral (796) 796
infant (794) 794
protease inhibitors (793) 793
antiretroviral therapy, highly active - methods (781) 781
infections (775) 775
prospective studies (772) 772
clinical trials (769) 769
usage (766) 766
hiv protease inhibitors - administration & dosage (752) 752
drug resistance (751) 751
social sciences (740) 740
antiretroviral agents (736) 736
hiv protease inhibitors - therapeutic use (729) 729
science & technology - other topics (725) 725
medical research (722) 722
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (18063) 18063
German (240) 240
Spanish (208) 208
French (126) 126
Portuguese (93) 93
Japanese (72) 72
Russian (27) 27
Italian (20) 20
Dutch (18) 18
Chinese (15) 15
Danish (14) 14
Norwegian (10) 10
Swedish (9) 9
Polish (8) 8
Hebrew (5) 5
Czech (3) 3
Finnish (2) 2
Turkish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Science (American Association for the Advancement of Science), ISSN 1095-9203, 07/2010, Volume 329, Issue 5996, pp. 1168 - 1174
The Centre for the AIDS Program of Research in South Africa (CAPRISA) 004 trial assessed the effectiveness and safety of a 1% vaginal gel formulation of... 
Human sexual behavior | HIV infections | Antiinfectives | Gels | HIV | RESEARCH ARTICLES | Placebos | Experimentation | AIDS | Infections | Condoms | Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Prevention | Tenofovir | Anti-infective agents | Research | HIV infection | Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 06/2012, Volume 379, Issue 9835, pp. 2429 - 2438
Summary Background The HIV integrase strand transfer inhibitor elvitegravir (EVG) has been co-formulated with the CYP3A4 inhibitor cobicistat (COBI),... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | HIV-1 | Humans | Middle Aged | Male | Thiazoles - administration & dosage | Carbamates - administration & dosage | Anti-HIV Agents - administration & dosage | Tenofovir | Atazanavir Sulfate | Adult | Female | Emtricitabine | Adenine - analogs & derivatives | Pyridines - administration & dosage | Double-Blind Method | Ritonavir - administration & dosage | Deoxycytidine - administration & dosage | Adenine - administration & dosage | Organophosphonates - administration & dosage | Quinolones - administration & dosage | HIV Infections - drug therapy | Oligopeptides - administration & dosage | Cobicistat | Deoxycytidine - analogs & derivatives | Drug Combinations | Antiviral agents | Patient outcomes | Dosage and administration | Research | Comparative analysis | Drug therapy | HIV infection | Anti-HIV agents | Antiretroviral drugs | Bone density | Pharmaceutical industry | Human immunodeficiency virus--HIV | Pneumonia | Laboratories | Ritonavir | Liver | Infections | Drug resistance | Evidence-based medicine | Hepatitis | Randomization | All terrain vehicles | Creatinine | Integrase | Data processing | Proteinase inhibitors | Behavior disorders | Ribonucleic acid--RNA | Patients | Cholesterol | Glomerular filtration rate | Protease inhibitors | Interactive systems | Index Medicus | Abridged Index Medicus
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 238 - 246
Summary Background Efavirenz with tenofovir-disoproxil-fumarate and emtricitabine is a preferred antiretroviral regimen for treatment-naive patients infected... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Rilpivirine | HIV Reverse Transcriptase - antagonists & inhibitors | Humans | Middle Aged | Male | Anti-HIV Agents - administration & dosage | Nitriles - administration & dosage | Tenofovir | Deoxycytidine - therapeutic use | Adenine - adverse effects | Adenine - therapeutic use | Adult | Anti-HIV Agents - therapeutic use | Deoxycytidine - adverse effects | Female | Reverse Transcriptase Inhibitors - therapeutic use | Acquired Immunodeficiency Syndrome - virology | Acquired Immunodeficiency Syndrome - ethnology | Emtricitabine | Adenine - analogs & derivatives | Benzoxazines - administration & dosage | Double-Blind Method | Drug Administration Schedule | Organophosphonates - therapeutic use | HIV-1 - drug effects | Pyrimidines - administration & dosage | Anti-HIV Agents - adverse effects | Deoxycytidine - administration & dosage | Organophosphonates - adverse effects | Benzoxazines - adverse effects | Treatment Outcome | HIV-1 - genetics | Acquired Immunodeficiency Syndrome - drug therapy | Adenine - administration & dosage | Benzoxazines - therapeutic use | Organophosphonates - administration & dosage | Pyrimidines - therapeutic use | Pyrimidines - adverse effects | Aged | Mutation | Nitriles - adverse effects | Viral Load - drug effects | Deoxycytidine - analogs & derivatives | Nitriles - therapeutic use | Dosage and administration | Efavirenz | Patient outcomes | Clinical trials | Antiretroviral drugs | Drug therapy | Human immunodeficiency virus--HIV | Index Medicus | Abridged Index Medicus
Journal Article
Lancet, The, ISSN 0140-6736, 2012, Volume 379, Issue 9835, pp. 2439 - 2448
Journal Article
PLoS pathogens, ISSN 1553-7374, 09/2015, Volume 11, Issue 9, pp. e1005142 - e1005142
Journal Article
Journal of Hepatology, ISSN 0168-8278, 2010, Volume 54, Issue 6, pp. 1114 - 1122
..., post-transplant HCV infection, hemodialysis patients, and others [3]. The HCV protease inhibitor BILN 2061 was the first agent in man to specifically target HCV... 
Gastroenterology and Hepatology | Antiviral | Resistant variants | Hepatitis C virus | Pegylated interferon | Ribavirin | Gastroenterology & Hepatology | Life Sciences & Biomedicine | Science & Technology | Antiviral Agents - pharmacokinetics | Hepatitis C - drug therapy | Protease Inhibitors - pharmacokinetics | Humans | Middle Aged | Hepacivirus - genetics | Male | Thiazoles - administration & dosage | Recombinant Proteins | Oligopeptides - adverse effects | Thiazoles - adverse effects | Thiazoles - pharmacokinetics | Protease Inhibitors - pharmacology | Hepatitis C - blood | Ribavirin - administration & dosage | Protease Inhibitors - administration & dosage | Protease Inhibitors - adverse effects | Adult | Female | Hepacivirus - drug effects | Antiviral Agents - pharmacology | Double-Blind Method | Oligopeptides - pharmacokinetics | Carrier Proteins - antagonists & inhibitors | Viral Nonstructural Proteins - genetics | Antiviral Agents - administration & dosage | Polyethylene Glycols - administration & dosage | Interferon-alpha - administration & dosage | Drug Resistance, Viral - genetics | Hepacivirus - enzymology | Antiviral Agents - adverse effects | Hepatitis C - virology | Oligopeptides - administration & dosage | Thiazoles - pharmacology | Oligopeptides - pharmacology | Viral Load - drug effects | Viral Nonstructural Proteins - antagonists & inhibitors | Medical colleges | Antiviral agents | Care and treatment | Safety and security measures | Hotels and motels | Immunodeficiency | Aspartate | Biological response modifiers | HIV (Viruses) | Anti-HIV agents | Complications and side effects | Protease inhibitors | Proteases | Genetic aspects | Hepatitis C | Index Medicus | Viral Nonstructural Proteins | Oligopeptides | Polyethylene Glycols | Interferon-alpha | Protease Inhibitors | Drug Resistance, Viral | Antiviral Agents | Viral Load | Life Sciences | Thiazoles | Hepacivirus | Carrier Proteins | Cancer
Journal Article
Nature communications, ISSN 2041-1723, 01/2018, Volume 9, Issue 1, pp. 2 - 2
Journal Article
Lancet, The, ISSN 0140-6736, 2011, Volume 378, Issue 9787, pp. 279 - 281
[...] there is improved clarity about the threshold concentration of tenofovir that is likely to protect against HIV, the goal in future clinical trials of... 
Internal Medicine | Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antiretroviral drugs | Disease transmission | Research & development--R&D | Drug dosages | Human immunodeficiency virus--HIV | Technological change | Index Medicus | Abridged Index Medicus
Journal Article